MYH9 and adenocarcinoma: We have reported that MYH9 is expressed in a subset of NSCLC, and its expression is related to the adenocarcinoma histology, poorer differentiation, intratumoral vascular invasion, intratumoral lymphatic invasion, and a poorer prognosis.